<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEFOXITIN SODIUM</span><br/>(se-fox'i-tin)<br/><span class="topboxtradename">Mefoxin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">second-generation cephalosporin</span><br/><b>Prototype: </b>Cefonicid sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 g, 2 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic, broad-spectrum beta-lactam antibiotic derivative of cephamycin C (produced by <i>Streptomyces lactamdurans</i>). Classified as second generation cephalosporin; structurally and pharmacologically related to cephalosporins and penicillins.
         Antimicrobial spectrum of activity resembles that of cefonicid. Considerably less active than most cephalosporins against
         <i>Staphylococci</i>. Preferentially binds to one or more of the penicillin-binding proteins (PBP) located on cell walls of susceptible organisms.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It shows enhanced activity against a wide variety of gram-negative organisms and is effective for mixed aerobic-anaerobic
         infections. Effectively treats gynecologic, bone and joint and intra-abdominal infections, gonorrhea, skin and urinary tract
         infections, and is used for surgical prophylaxis, reducing or eliminating infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Infections caused by susceptible organisms in the lower respiratory tract, urinary tract, skin and skin structures, bones
         and joints; also intra-abdominal endocarditis, gynecological infections, septicemia, uncomplicated gonorrhea, and perioperative
         prophylaxis in prosthetic arthroplasty or cardiovascular surgery. May be cephalosporin of choice for mixed aerobic-anaerobic
         infections (e.g., <i>Bacteroides fragilis</i>).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cephalosporins and related antibiotics; pregnancy (category B), lactation. Safe use in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of sensitivity to penicillin or other allergies, particularly to drugs; impaired renal function.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 12 g q68h, up to 12 g/d<br/><span class="rdage">Child <i>&gt;3 mo</i>
                  				:</span> <span class="rdroute">IV/IM</span> 80160 mg/kg/d in 46 divided doses (max: 12 g/d)<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV/IM</span> 90100 mg/kg/d divided q8h<br/><br/><span class="indicationtitle">Surgical Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 2 g 3060 min before surgery, then 2 g q6h for 24 h<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> 3040 mg/kg 3060 min before surgery, then 2 g q6h for 24 h<br/><br/><span class="indicationtitle">Uncomplicated Gonorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 2 g given concurrently with 1 g probenecid PO<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute each 1 g with 2 mL sterile water for injection or 0.5 or 1% lidocaine hydrochloride (without epinephrine),
            used to reduce discomfort of IM injection. After reconstitution for IM use, shake vial and allow solution to stand until it
            becomes clear.
         </li>
<li>Administer IM injections deep into large muscle mass such as upper outer quadrant of gluteus maximus. Aspirate before injecting
            drug. Rotate injection sites.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to neonates, infants and children: Verify correct IV concentration and rate of infusion/injection with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute each 1 g with 10 mL sterile water, D5W, or NS.   <span class="methodtype">Intermittent:</span> Following reconstitution, dilute 12 g in 50100 mL of D5W or NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 35 min.   <span class="methodtype">Intermittent:</span> Give over 15 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<span class="classification">aminoglycosides</span>, <b>ranitidine.</b>
<span class="incompattype">Y-site:</span>
<span class="classification">aminoglycosides</span>, <b>filgrastim,</b>
<b>hetastarch,</b>
<b>pentamidine,</b>
<b>vancomycin.</b>
</p>
<ul>
<li>Reconstituted solution may become discolored (usually light yellow to amber) if exposed to high temperatures; however, potency
                     is not affected. Solution may be cloudy immediately after reconstitution; let stand and it will clear.
                  </li>
</ul>
</td>
</tr>
</table>
<ul>
<li>After reconstitution, solution is stable for 24 h at 25° C (77° F); 7 d when refrigerated at 4° C (39°
            F), or 30 wk when frozen at 20° C (4° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Drug fever, eosinophilia, superinfections, local reactions: pain, tenderness, and induration (IM site), thrombophlebitis (IV
      site). <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea,</span>
<span class="speceff-life">pseudomembranous colitis</span>. <span class="typehead">Skin:</span> Rash, <span class="speceff-life">exfoliative dermatitis</span>, pruritus, urticaria. <span class="typehead">Urogenital:</span> Nephrotoxicity, interstitial nephritis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Cefoxitin causes false-positive (black-brown or green-brown color) <span class="alt">urine glucose</span> reaction with <span class="alt">copper reduction reagents</span> such as <span class="alt">Benedict's</span> or <span class="alt">Clinitest,</span> but not with <span class="alt">enzymatic glucose oxidase reagents</span>
<span class="alt">(Clinistix, TesTape).</span> With high doses, falsely elevated <span class="alt">serum and urine creatinine</span> (with <span class="alt">Jaffee reaction</span>) reported. False-positive <span class="alt">direct Coombs' test</span> (may interfere with <span class="alt">cross-matching procedures</span> and <span class="alt">hematologic studies</span>) has also been reported.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid</b> decreases renal elimination of cefoxitin. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 2030 min after IM; 5 min after IV. <span class="typehead">Distribution:</span> Poor CNS penetration even with inflamed meninges; widely distributed in body tissues including pleural, synovial, and ascitic
      fluid and bile; crosses placenta. <span class="typehead">Elimination:</span> 85% excreted unchanged in urine in 6 h, small amount excreted in breast milk. <span class="typehead">Half-Life:</span> 4560 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine previous hypersensitivity to cephalosporins, penicillins, and other drug allergies before therapy is initiated.</li>
<li>Lab tests: Perform culture and sensitivity testing prior to and periodically during therapy. Periodic renal function tests.</li>
<li>Inspect injection sites regularly. Report evidence of inflammation and patient's complaint of pain.</li>
<li>Monitor I&amp;O rates and pattern: Nephrotoxicity occurs most frequently in patients &gt;50 y, in patients with impaired renal function,
            the debilitated, and in patients receiving high doses or other nephrotoxic drugs.
         </li>
<li>Be alert to S&amp;S of superinfections (see Appendix F). This condition is most apt to occur in older adult patients, especially
            when drug has been used for prolonged period.
         </li>
<li>Report onset of diarrhea (may be dose related). If severe, pseudomembranous colitis (see Signs &amp; Symptoms, Appendix F) must
            be ruled out. Older adult patients are especially susceptible.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly S&amp;S of superinfection (see Appendix F).</li>
<li>Report watery or bloody loose stools or severe diarrhea.</li>
<li>Report severe vomiting or stomach pain.</li>
<li>Report infusion site swelling, pain, or redness.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>